Ibrutinib, a Bruton’s tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil.

Slides:

Advertisements

Similar presentations

A bioinformatics approach to identify patients with symptomatic peanut allergy using peptide microarray immunoassay Jing Lin, PhD, Francesca M. Bruni,

Advertisements

Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.

The use of serum-specific IgE measurements for the diagnosis of peanut, tree nut, and seed allergy Jennifer M. Maloney, MD, Magnus Rudengren, BSc, Staffan.

Wen Chin Chiang, MRCPCH, Chiung-Hui Huang, PhD, Genevieve V

Allergen immunotherapy: A practice parameter third update

Early suppression of basophil activation during allergen-specific immunotherapy by histamine receptor 2 Natalija Novak, MD, Nihal Mete, MD, Caroline.

Clarification concerning amoxicillin skin testing

Alexandra Kazaks, MA, RD, Janet Y. Uriu-Adams, PhD, Judith S

Margaretha A. Faber, MD, Vito Sabato, MD, Chris H

Kyoung-Bok Min, MD, PhD, Jin-Young Min, PhD

Delayed clinical and ex vivo response to mammalian meat in patients with IgE to galactose-alpha-1,3-galactose Scott P. Commins, MD, PhD, Hayley R. James,

Advances in food allergy in 2015

Role of the basophil activation test in the diagnosis of local allergic rhinitis Enrique Gómez, PhD, Paloma Campo, MD, PhD, Carmen Rondón, MD, PhD, Esther.

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Giant ragweed specific immunotherapy is not effective in a proportion of patients sensitized to short ragweed: Analysis of the allergenic differences.

Making the Most of In Vitro Tests to Diagnose Food Allergy

Bruton tyrosine kinase mediates TLR9-dependent human dendritic cell activation Vassilios Lougaris, MD, Manuela Baronio, PhD, Massimiliano Vitali, PhD,

Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD

Is 9 more than 2 also in allergic airway inflammation?

Mass cytometry profiling the response of basophils and the complete peripheral blood compartment to peanut Leticia Tordesillas, PhD, Adeeb H. Rahman,

Loss of allergenic proteins during boiling explains tolerance to boiled peanut in peanut allergy Paul J. Turner, FRACP, PhD, Sam Mehr, FRACP, Rebekah.

Clavulanic acid can be the component in amoxicillin-clavulanic acid responsible for immediate hypersensitivity reactions Maria José Torres, MD, PhD,

Management of post–liver transplant–associated IgE-mediated food allergy in children Ghyath Maarof, MD, PhD, Roman Krzysiek, MD, PhD, Jean-Luc Décline,

A focused parameter update: Hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor–associated angioedema

Nonadherence to Asthma Treatment: Getting Unstuck

Peter M. Wolfgram, MD, David B. Allen, MD

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations Raymond G.

Loss of syk kinase during IgE-mediated stimulation of human basophils

Reply Journal of Allergy and Clinical Immunology

Suppression of the basophil response to allergen during treatment with omalizumab is dependent on 2 competing factors Donald W. MacGlashan, MD, PhD,

Donald W. MacGlashan, MD, PhD, Sarbjit S. Saini, MD

Debra J. Palmer, PhD, Thomas R. Sullivan, BMa&CompSc(Hons), Michael S

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Biosimilars and drug development in allergic and immunologic diseases

Individual IL-3 priming is crucial for consistent in vitro activation of donor basophils in patients with chronic urticaria Thomas Gentinetta, MSc, Tatjana.

Comparison of asthma prevalence among African American teenage youth attending public high schools in rural Georgia and urban Detroit Dennis R. Ownby,

John A. Eckman, MD, Patricia M

What is an “eosinophilic phenotype” of asthma?

Medication use in children with asthma in Finland from 1995 to 2006

Autophagy: Nobel Prize 2016 and allergy and asthma research

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Advances in the approach to the patient with food allergy

Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? Marianne Witten, MD, PhD, Hans-Jørgen Malling, MD, Lars.

Alexandra Kazaks, MA, RD, Janet Y. Uriu-Adams, PhD, Judith S

New pathways for itching in patients with atopic dermatitis?

Sara Paveglio, PhD, MS, Erin Bennett, MS, Kelly L. Hawley, PhD, Adam P

Syk expression and IgE-mediated histamine release in basophils as biomarkers for predicting the clinical efficacy of omalizumab Donald W. MacGlashan,

Asifa K. Zaidi, PhD, Sarbjit S. Saini, MD, Donald W

Martin Brasholt, MD, Florent Baty, PhD, Hans Bisgaard, MD, DMSci

Anaphylaxis Journal of Allergy and Clinical Immunology

An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment Eli O. Meltzer, MD, Robert B. Berkowitz,

Jessica H. Savage, MD, MHS, Elizabeth C. Matsui, MD, MHS, Robert A

Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity James N. Francis, PhD, Louisa.

Clinical safety of Food Allergy Herbal Formula-2 (FAHF-2) and inhibitory effect on basophils from patients with food allergy: Extended phase I study

Early improvement in basophil sensitivity predicts symptom relief with grass pollen immunotherapy Johannes Martin Schmid, MD, Peter Adler Würtzen, PhD,

Macrolide antibiotics and asthma treatment

Asthma: The past, future, environment, and costs

Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.

Placental transfer of allergen-specific IgG but not IgE from a specific immunotherapy– treated mother Sabine Flicker, PhD, Katharina Marth, MD, Heinz.

Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding Sven.

Kinase inhibitors in clinical practice: An expanding world

The GILL study: Glycerin-induced local reactions in immunotherapy

The use of serum-specific IgE measurements for the diagnosis of peanut, tree nut, and seed allergy Jennifer M. Maloney, MD, Magnus Rudengren, BSc, Staffan.

The effects of gastric digestion on codfish allergenicity

An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment Eli O. Meltzer, MD, Robert B. Berkowitz,

Natural history of cow’s milk allergy

The Editors' Choice Journal of Allergy and Clinical Immunology

Advances in mechanisms of allergic disease in 2016

Presentation transcript:

Ibrutinib, a Bruton’s tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity Jennifer A. Regan, MD, PhD, Yun Cao, MD, Melanie C. Dispenza, MD, PhD, Shuo Ma, MD, PhD, Leo I. Gordon, MD, Adam M. Petrich, MD, Bruce S. Bochner, MD Journal of Allergy and Clinical Immunology Volume 140, Issue 3, Pages 875-879.e1 (September 2017) DOI: 10.1016/j.jaci.2017.03.013 Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Ibrutinib inhibits basophil and mast cell activation in 2 subjects prescribed ibrutinib for CLL treatment. A, Demographic characteristics, BTK inhibitor clinical indication, ibrutinib dose, and IgE levels are listed for each subject. B, Skin test responses to cat allergen (subject 1) and ragweed (subject 2) before and during ibrutinib treatment (420 mg daily) in 2 patients being treated for CLL. C, Basophil activation responses to anti-IgE (72% and 89% positive, respectively, before starting ibrutinib) or fMLP (12% and 16% positive, respectively, before starting ibrutinib) are shown for these same 2 subjects. Journal of Allergy and Clinical Immunology 2017 140, 875-879.e1DOI: (10.1016/j.jaci.2017.03.013) Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Ibrutinib inhibits basophil and mast cell activation in 2 subjects prescribed ibrutinib for CLL treatment. A, Demographic characteristics, BTK inhibitor clinical indication, ibrutinib dose, and IgE levels are listed for each subject. B, Skin test responses to cat allergen (subject 1) and ragweed (subject 2) before and during ibrutinib treatment (420 mg daily) in 2 patients being treated for CLL. C, Basophil activation responses to anti-IgE (72% and 89% positive, respectively, before starting ibrutinib) or fMLP (12% and 16% positive, respectively, before starting ibrutinib) are shown for these same 2 subjects. Journal of Allergy and Clinical Immunology 2017 140, 875-879.e1DOI: (10.1016/j.jaci.2017.03.013) Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Ibrutinib and acalabrutinib inhibit basophil activation in vitro as measured by the BAT in whole blood samples obtained from healthy volunteers. Whole blood samples were obtained from healthy volunteers and preincubated with the indicated concentrations of the drug for 30 minutes; then, BAT was performed with the addition of anti-IgE or fMLP. Levels of anti-IgE and fMLP BAT from which the values were normalized averaged 62% ± 9% and 26% ± 1% positive. Values represent mean ± SEM (N = 3-4). Journal of Allergy and Clinical Immunology 2017 140, 875-879.e1DOI: (10.1016/j.jaci.2017.03.013) Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions